Roivant director sells 10,000 shares after option exercise

Roivant Sciences Ltd. director Meghan Fitzgerald reported an option exercise paired with an open-market sale of common shares.

Rhea-AI Filing Summary

Roivant Sciences Ltd. director Meghan Fitzgerald reported an option exercise paired with an open-market sale of common shares. She exercised stock options to acquire 10,000 common shares at $8.80 per share and on the same date sold 10,000 common shares at an average price of $34.90 per share.

Following these transactions, Fitzgerald directly holds 42,963 common shares of Roivant Sciences. The derivative entry shows 38,578 stock options remaining after the exercise, indicating she continues to have a meaningful option position as well as a direct equity stake.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Fitzgerald Meghan

Role Director

Sold 10,000 shs ($349K)

Approx. gross sale proceeds $349K

Approx. exercise cost $88K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	10,000	$0.00	$0.00
Exercise	Common Shares	10,000	$8.80	$88K
Sale	Common Shares	10,000	$34.90	$349K

Holdings After Transaction: Stock Option (Right to Buy) — 38,578 contracts (Direct); Common Shares — 42,963 shares (Direct)

Footnotes (1)

1. F1. Award of stock options to purchase Common Shares that is fully vested.

Key Figures

Common shares sold: 10,000 shares Sale price: $34.90 per share Options exercised: 10,000 shares +3 more

6 metrics

Common shares sold 10,000 shares Open-market sale at $34.90 per share

Sale price $34.90 per share Average price for 10,000 common shares sold

Options exercised 10,000 shares Stock options exercised at $8.80 per share

Exercise price $8.80 per share Conversion or exercise price for stock options

Shares owned after 42,963 shares Direct common share ownership following transactions

Options remaining 38,578 options Stock Option (Right to Buy) balance after exercise

Key Terms

open-market sale, derivative exercise/conversion, Stock Option (Right to Buy), Common Shares

4 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action": "derivative exercise/conversion""

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

Common Shares financial

"security_title": "Common Shares""

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Roivant Sciences (ROIV) director Meghan Fitzgerald report?

Meghan Fitzgerald reported an exercise-and-sell pattern. She exercised options to acquire 10,000 Roivant Sciences common shares at $8.80 per share, then sold 10,000 common shares in an open-market transaction at an average price of $34.90 per share.

How many Roivant Sciences (ROIV) shares did Meghan Fitzgerald sell and at what price?

Fitzgerald sold 10,000 Roivant Sciences common shares in an open-market transaction. The reported average sale price was $34.90 per share, reflecting a discretionary disposition of a portion of her directly held common share position on that transaction date.

What stock options did Meghan Fitzgerald exercise in Roivant Sciences (ROIV)?

She exercised a Stock Option (Right to Buy) for 10,000 underlying common shares at a conversion or exercise price of $8.80 per share. This derivative exercise converted part of her option holdings into common shares on the same reported date.

How many Roivant Sciences (ROIV) shares does Meghan Fitzgerald own after the reported transactions?

After the reported transactions, Fitzgerald directly owns 42,963 Roivant Sciences common shares. This figure reflects her direct common share ownership immediately following the option exercise and subsequent open-market sale of 10,000 common shares disclosed in the filing.

How many Roivant Sciences (ROIV) stock options remain for Meghan Fitzgerald after the exercise?

The derivative holdings table shows 38,578 stock options remaining following the exercise of 10,000 options. These options, described as Stock Option (Right to Buy), continue to provide additional potential exposure to Roivant Sciences common shares beyond her direct share ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 07:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fitzgerald Meghan

(Last) (First) (Middle)

C/O ROIVANT SCIENCES LTD.

7TH FLOOR, 50 BROADWAY

(Street)

LONDON SW1H 0DB

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	06/30/2026		M		10,000	A	$8.8	52,963	D
Common Shares	06/30/2026		S		10,000	D	$34.9	42,963	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.8	06/30/2026		M			10,000	(1)	04/19/2033	Common Stock	10,000	$0	38,578	D

Explanation of Responses:

1. Award of stock options to purchase Common Shares that is fully vested.

Remarks:

	By: /s/ Richard Pulik, as Attorney-in-Fact for Meghan FitzGerald	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)